Literature DB >> 15548688

Inhibition of melanoma growth and metastasis by ATF2-derived peptides.

Anindita Bhoumik1, Lisa Gangi, Ze'ev Ronai.   

Abstract

The resistance of melanoma to apoptosis, as well as its growth and metastasis capabilities, can be overcome by expression of a peptide derived from amino acid (aa) 51 to 100 of ATF2. Here we show that expression of ATF2((51-100)) in human melanoma cells reduced their growth in nude mice, which was additionally inhibited upon treatment with protein kinase inhibitors UCN-01 or SB203580. Injection of a fusion protein consisting of HIV-TAT and aa 51 to 100 of ATF2 into SW1 melanomas efficiently inhibits their growth and their metastasis up to complete regression. Additionally, expression of a 10aa peptide that corresponds to aa 51 to 60 of ATF2 sensitizes melanoma cells to spontaneous apoptosis, which coincides with activation of caspase 9 and poly(ADP-ribose) polymerase cleavage, and inhibit their growth in vivo. The 10aa peptide increases the association of c-Jun NH(2)-terminal kinase with c-Jun but not with ATF2, resulting in concomitant increase in TRE-mediated transcription. Our study points to mechanisms underlying the activities of the ATF2 peptide while highlighting its possible use in drug design.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548688     DOI: 10.1158/0008-5472.CAN-04-0714

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease.

Authors:  Gregory Watson; Ze'ev A Ronai; Eric Lau
Journal:  Pharmacol Res       Date:  2017-02-15       Impact factor: 7.658

3.  Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.

Authors:  Sulochana S Bhandarkar; Jacqueline Bromberg; Carol Carrillo; Ponniah Selvakumar; Rajendra K Sharma; Betsy N Perry; Baskaran Govindarajan; Levi Fried; Allie Sohn; Kalpana Reddy; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

4.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

5.  Crosstalk between TGF-beta and MAPK signaling during corneal wound healing.

Authors:  Kazuto Terai; Mindy K Call; Hongshan Liu; Shizuya Saika; Chia-Yang Liu; Yasuhito Hayashi; Tai-ichiro Chikama; Jianhua Zhang; Noriko Terai; Candace W-C Kao; Winston W-Y Kao
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-17       Impact factor: 4.799

6.  Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2.

Authors:  Tal Varsano; Eric Lau; Yongmei Feng; Marine Garrido; Loribelle Milan; Susanne Heynen-Genel; Christian A Hassig; Ze'ev A Ronai
Journal:  Clin Cancer Res       Date:  2013-04-15       Impact factor: 12.531

7.  Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.

Authors:  Sita Aggarwal; Seung-Wook Kim; Seung-Hee Ryu; Wen-Cheng Chung; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

8.  Preclinical studies of celastrol and acetyl isogambogic acid in melanoma.

Authors:  Sabiha Abbas; Anindita Bhoumik; Russell Dahl; Stefan Vasile; Stan Krajewski; Nicholas D P Cosford; Ze'ev A Ronai
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

9.  Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-02-17       Impact factor: 3.905

10.  The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation.

Authors:  Eric Lau; Yongmei Feng; Giuseppina Claps; Michiko N Fukuda; Ally Perlina; Dylan Donn; Lucia Jilaveanu; Harriet Kluger; Hudson H Freeze; Ze'ev A Ronai
Journal:  Sci Signal       Date:  2015-12-08       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.